- Home
- CZNC vs GNFT Comparison
CZNC vs GNFT Comparison
Compare CZNC & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- GNFT
- Stock Information
- Founded
- CZNC 1864
- GNFT 1999
- Country
- CZNC United States
- GNFT France
- Employees
- CZNC N/A
- GNFT N/A
- Industry
- CZNC Major Banks
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CZNC Finance
- GNFT Health Care
- Exchange
- CZNC Nasdaq
- GNFT Nasdaq
- Market Cap
- CZNC 287.4M
- GNFT 214.5M
- IPO Year
- CZNC N/A
- GNFT 2019
- Fundamental
- Price
- CZNC $19.75
- GNFT N/A
- Analyst Decision
- CZNC
- GNFT Strong Buy
- Analyst Count
- CZNC 0
- GNFT 1
- Target Price
- CZNC N/A
- GNFT $13.00
- AVG Volume (30 Days)
- CZNC 37.5K
- GNFT 4.2K
- Earning Date
- CZNC 08-06-2025
- GNFT 04-24-2025
- Dividend Yield
- CZNC 5.67%
- GNFT N/A
- EPS Growth
- CZNC 15.34
- GNFT N/A
- EPS
- CZNC 1.75
- GNFT 0.03
- Revenue
- CZNC $108,114,000.00
- GNFT $73,187,701.00
- Revenue This Year
- CZNC $6.78
- GNFT $15.98
- Revenue Next Year
- CZNC $4.59
- GNFT N/A
- P/E Ratio
- CZNC $11.30
- GNFT $125.30
- Revenue Growth
- CZNC 5.33
- GNFT 105.01
- 52 Week Low
- CZNC $16.73
- GNFT $2.55
- 52 Week High
- CZNC $22.68
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- CZNC 62.19
- GNFT 47.81
- Support Level
- CZNC $18.88
- GNFT $3.61
- Resistance Level
- CZNC $19.85
- GNFT $3.95
- Average True Range (ATR)
- CZNC 0.46
- GNFT 0.14
- MACD
- CZNC 0.15
- GNFT -0.01
- Stochastic Oscillator
- CZNC 93.75
- GNFT 57.01
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.